Corvus Pharmaceuticals (CRVS) Assets Average (2016 - 2026)

Corvus Pharmaceuticals' Assets Average history runs 11 years deep, the most recent figure standing at $162.2 million for Q1 2026.

• On a quarterly basis, Assets Average rose 152.69% year-over-year to $162.2 million in Q1 2026; TTM through Mar 2026 was $162.2 million, a 152.69% increase from a year earlier, with the FY2025 full-year figure at $70.0 million, up 22.34% from the prior year.
• Assets Average rose to $162.2 million in Q1 2026 per CRVS's latest filing, from $75.8 million in the prior quarter.
• Across five years, Assets Average topped out at $162.2 million in Q1 2026 and bottomed at $42.8 million in Q1 2024.
• The 5-year median for Assets Average is $64.2 million (2025), against an average of $74.7 million.
• Across the five-year window, Assets Average plunged 40.03% in 2023 and surged 152.69% in 2026, its largest moves.
• Year by year, Assets Average stood at $74.3 million in 2022, then plunged by 34.39% to $48.7 million in 2023, then surged by 31.0% to $63.9 million in 2024, then increased by 18.69% to $75.8 million in 2025, then surged by 113.94% to $162.2 million in 2026.
• Per Business Quant, the three latest CRVS Assets Average figures stand at $162.2 million (Q1 2026), $75.8 million (Q4 2025), and $85.0 million (Q3 2025).